An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD)

Exclusion Criteria

• - Previous enrollment in the present study.
• - Significant clinical illness within 2 weeks prior to the first dose of study medication or a significant illness during the study.
• - Use of a PPI, including PRILOSEC OTC®, within 21 days of Screening (Visit 1) or at anytime during the study (Visit 1 through Visit 4).
• - Daily therapy with an H2 RA within 14 days of Screening (Visit 1): eg, ranitidine (ZANTAC®), cimetidine (TAGAMET®), nizatidine (AXID®), famotidine (PEPCID®) (occasional use; ie, less than daily, is permitted).
• - Use of H2 RAs at any frequency are prohibited throughout the entire study (Visit 1 through Visit 4).
• - A history of gastric or esophageal surgery (including, but not limited to, Nissen fundoplication and bariatric surgery), except for simple closure of a perforated ulcer or procedures that would not affect the study as determined by the Clinical Study Team physician at AstraZeneca.
• - Clinically significant gastrointestinal (GI) bleeding (eg, melena, frank hematochezia) within 3 days of Screening (Visit 1) or noted at the time of baseline EGD.
• - Non-acid related etiologies of esophagitis (eg, pill-induced, caustic ingestion or eosinophilic esophagitis).
• Generalized bleeding disorders resulting from hemorrhagic diathesis (such as abnormalities in clotting factors or platelets).